Maurizio Di Liberto

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Cell Cycle Dysregulation in Mantle Cell Lymphoma”.

Cell Cycle Dysregulation in Mantle Cell Lymphoma

Hematology/Oncology Clinics of North America(2020)10.1016/j.hoc.2020.05.003

N/A

0DataRank · unranked

15 citations

Xiangao Huang, Maurizio Di Liberto, Selina Chen‐Kiang, Kevin Wang

Radiotherapy Delivered before CDK4/6 Inhibitors Mediates Superior Therapeutic Effects in ER+ Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3871

N/A

0DataRank · unranked

71 citations

Aitziber Buqué, Takahiro Yamazaki, Norma Bloy, Maurizio Di Liberto, Selina Chen‐Kiang +3 more

A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas

Journal of Clinical Investigation(2022)10.1172/jci160767

N/A

0DataRank · unranked

26 citations

Inah Hwang, Heng Pan, Jun Yao, Lapo Alinari, Eddie L. Imada +19 more

PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma

Blood Advances(2023)10.1182/bloodadvances.2023009906

N/A

0DataRank · unranked

16 citations

Inah Hwang, Shelby Sloan, Claire Hinterschied, JoBeth Helmig-Mason, Mackenzie Long +19 more

Resistance to PRMT5-targeted therapy in mantle cell lymphoma

Blood Advances(2023)10.1182/bloodadvances.2023010554

N/A

0DataRank · unranked

11 citations

Shirsha Koirala, Shelby Sloan, Fiona Brown-Burke, Christoph Weigel, Lynda Villagomez +19 more